Table 3.
Decreases in mortality risk associated with kidney transplantation in the sickle cell disease and control groups
| Treatment Modality | Group | Absolute Risk Difference, Percentage Points (98.75% CI) | |||
|---|---|---|---|---|---|
| 1 Year Post-KT | 3 Years Post-KT | 5 Years Post-KT | 10 Years Post-KT | ||
| Match set 1 | Sickle cell | 6.1 (−0.8 to 13.0) | 15.3 (3.9 to 26.7) | 23.8 (9.6 to 38.0) | 20.3 (0.9 to 39.8) |
| Control | 0.7 (0.5 to 0.8) | 6.6 (6.4 to 6.9) | 12.7 (12.4 to 13.1) | 19.8 (19.2 to 20.4) | |
| Match set 2 | Sickle cell | 6.1 (−0.8 to 13.0) | 15.3 (3.9 to 26.7) | 23.8 (9.6 to 38.0) | 20.3 (0.9 to 39.8) |
| Control | 0.6 (0.3 to 0.8) | 5.6 (5.1 to 6.1) | 11.0 (10.3 to 11.7) | 18.2 (17.1 to 19.3) | |
| Match set 3 | Sickle cell | 6.4 (−0.9 to 13.6) | 16.0 (4.3 to 27.8) | 25.3 (10.6 to 40.0) | 18.8 (−1.3 to 38.9) |
| Control | −1.2 (−3.0 to 0.6) | 1.0 (−2.3 to 4.3) | 6.1 (1.3 to 10.9) | 15.5 (6.9 to 24.1) | |
The 98.75% CIs were determined after Bonferroni correction for multiple comparisons. Match set 1 included all transplant recipients and waitlisted candidates in the controls. Match set 2 restricted the controls to only those who were identified as Black or African American. Match set 3 also involved variable-ratio (up to 1:5) matching of transplant recipients from the sickle cell group with transplant recipients from the controls, on the basis of age, sex, panel-reactive antibody, diabetes, previous KT, time on dialysis, and donor type (deceased versus living). CI, confidence interval; KT, kidney transplant.